We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)

This study has suspended participant recruitment.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00065572
First Posted: July 31, 2003
Last Update Posted: January 26, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
July 28, 2003
July 31, 2003
January 26, 2011
August 2003
February 2004   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00065572 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)
Not Provided
The purpose of this study is to assess the biological activity of ZD6126 in subjects with newly diagnosed metastatic renal cell carcinoma (stage IV).
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Drug: ZD6126
  • Drug: Placebo
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Suspended
Not Provided
February 2004
February 2004   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Newly diagnosed metastatic renal cell carcinoma
  • Suitable for nephrectomy

Exclusion Criteria:

  • Prior chemotherapy, biological therapy or radiation therapy for renal cell carcinoma or within the last 3 years for any other cancer
  • Significant cardiac event within 3 months of entry
  • Any history of coronary angioplasty or history of myocardial infarction
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00065572
D2820C00018
6126IL/00018
Not Provided
Not Provided
Not Provided
Not Provided
AstraZeneca
Not Provided
Not Provided
AstraZeneca
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP
To Top